Facteurs pronostiques des uvéites

Albaroudi, N.; Tijani, M.; Boutimzine, N.; Cherkaoui, O.; Laghmari, M.

doi:10.1016/j.jfo.2017.04.005

Cited by 5 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Uveitis-related ME is considered as a risk factor for severe vision loss 171. The prognosis depends on the etiology of the uveitis and also the severity of the ocular inflammation and the activity of the potentially coexisting systemic disease,172 for example a UME secondary to Adamantiades–Behçet disease will have a poorer prognosis compared to a sarcoidosis related UME.…”

Section: Prognosismentioning

confidence: 99%

<p>Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges</p>

Massa

Pipis

Adewoyin

et al. 2019

OPTH

View full text Add to dashboard Cite

Macular edema (ME) is the most common sight-threatening complication in uveitis. The diagnostic and therapeutic management of the uveitic macular edema (UME) might be challenging due to the complex diagnostic workup and the difficulties physicians face to find the underlying cause, and due to its usually recurrent nature and the fact that it can be refractory to conventional treatment. Some of the mild cases can be treated with topical steroids, which can be combined with non-steroid anti-inflammatory drugs. However, immunomodulators such as methotrexate, tacrolimus, azathioprine, cyclosporine and mycophenolate mofetil together with anti-tumor necrosis factor-α (anti-TNF alpha) monoclonal antibodies such as adalimumab and infliximab, may be required to control the inflammation and the associated ME in refractory cases, or when an underlying disease is present. This review of the literature will focus mostly on the non-infectious UME.

show abstract

Section: Prognosismentioning

confidence: 99%